Will fusion power get cheap? Don’t count on it.

Fusion power could provide a steady, zero-emissions source of electricity in the future—if companies can get plants built and running. But a new study suggests that even if that future arrives, it might not come cheap.

Technologies tend to get less expensive over time. Lithium-ion batteries are now about 90% cheaper than they were in 2013. But historically, different technologies tend to go through this curve at different rates. And the cost of fusion might not sink as quickly as the prices of batteries or solar.

It’s tricky to make any predictions about the cost of a technology that doesn’t exist yet. But when there’s billions of dollars of public and private funding on the line, it’s worth considering what assumptions we’re making about our future energy mix and its cost.

One crucial measure is a metric called experience rate—the percentage by which an energy technology’s cost declines every time capacity doubles. A higher figure means a quicker price drop and better economic gains with scaling.

Historically, the experience rate is 12% for onshore wind power, 20% for lithium-ion batteries, and 23% for solar modules. Other energy technologies haven’t gotten cheap quite as quickly—fission is at just 2%.

In the new study, published in Nature Energy, researchers aimed to improve predictions of fusion’s future price by estimating the technology’s experience rate. The team looked at three key characteristics that can correlate with experience rate: unit size, design complexity, and the need for customization. The larger and more complex a technology is, and/or the more it needs to be customized for different use cases, the lower the experience rate.

The researchers interviewed fusion experts, including public-sector researchers and those working at companies in the private sector. They had the experts evaluate fusion power plants on those characteristics and used that info to predict the experience rate. (One note here: The study focused only on magnetic confinement and laser inertial confinement, two of the leading fusion approaches, which together receive the vast majority of funding today. Other approaches could come with different cost benefits.)

Fusion plants will likely be relatively large, similar to other types of facilities (like coal and fission power plants) that rely on generating heat. They will probably need less customization than fission plants—largely because regulations and safety considerations should be simpler—but more than technologies like solar panels. And as for complexity, “there was almost unanimous agreement that fusion is incredibly complex,” says Lingxi Tang, a PhD candidate in the energy and technology policy group at ETH Zurich in Switzerland and one of the authors of the study. (Some experts said it was literally off the scale the researchers gave them.)

The final figure the researchers suggest for fusion’s experience rate is between 2% and 8%, meaning it will see a faster price reduction than nuclear power but not as dramatic an improvement as many common energy technologies being deployed today.

That means that it would take a lot of deployment—and likely quite a long time—for the price of building a fusion reactor to drop significantly, so electricity produced by fusion plants could be expensive for a while. And it’s a much slower rate than the 8% to 20% that many modeling studies assume today.

“On the whole, I think questions should be raised about current investment levels in fusion,” Tang says. (The US allocated over $1 billion to fusion in the 2024 fiscal year, and private-sector funding totaled $2.2 billion between July 2024 and July 2025.) “If you’re talking about decarbonization of the energy system, is this really the best use of public money?”

But some experts say that looking to the past to understand the future of energy prices might be misleading.“It’s a good exercise, but we have to be humble about how much we don’t know,” says Egemen Kolemen, a professor at the Princeton Plasma Physics Laboratory.

In 2000, many analysts predicted that solar power would remain expensive—but then production exploded and prices came crashing down, largely because China went all in, he says. “People weren’t exactly wrong then,” he adds. “They were just extrapolating what they saw into the future.”

How fast prices drop depends on regulations, geopolitical dynamics, and labor cost, he says: “We haven’t built the thing yet, so we don’t know.”

This article is from The Spark, MIT Technology Review’s weekly climate newsletter. To receive it in your inbox every Wednesday, sign up here.

STAT+: Will bargain-basement telehealth visits help pharma drive drug scripts?

The little pink pill recently got a retail boost. Addyi, a drug that treats low libido in premenopausal women, has been on the market for more than a decade after a controversial approval. But in December the Food and Drug Administration expanded its use, approving the daily drug for all women under 65. 

More women than ever now could qualify for the pill — and its maker, Sprout Pharmaceuticals, made it easy for them to find out. On its Instagram account, in Facebook ads, and on its website, Sprout shared how women could get a quick consult for an Addyi prescription: With a special code, PINKPILL, they could get a telehealth visit for just $10. 

Drugmakers have long used discount coupons to encourage patients to use their high-cost medications. Now, coupons can influence not just a drug’s out-of-pocket price, but the cost of consulting with a clinician who can prescribe it. 

For Addyi, those consultations and discounts are managed by a telehealth company called Prescribery — one of several that work with drugmakers to help patients “talk to a doctor now” about their products. “We give them the coupon codes that they can use, and they get to market it to drive additional business,” said Prescribery’s CEO and CFO Ross Pope. “That’s sort of our arrangement, where they’re driving more business, both for them and for us.”

As links between pharmaceutical companies and telehealth providers grow, health policy experts and legislators have sounded alarms. Telehealth companies can receive hundreds of thousands of dollars in pharma fees a year. Critics have questioned whether those partnerships break federal laws prohibiting financial kickbacks to induce prescribing, highlighting their potential to promote uncoordinated care and overprescription of unnecessary, and often expensive, branded medications. 

The same questions, they say, apply to coupons extended for a drug-specific telehealth visit. “These discount structures are one more piece of the same puzzle,” said Daniel Eisenkraft Klein, a postdoctoral fellow at the Program on Regulation, Therapeutics, and Law at Brigham and Women’s Hospital and Harvard Medical School. “It’s this big financial architecture that’s every step of the way designed to move patients toward the specific drug cheaply and quickly.” 

Continue to STAT+ to read the full story…

Opinion: Kennedy’s new silence on vaccines is political — and it won’t last

For the moment, Health and Human Services Secretary Robert F. Kennedy Jr. seems quieter and more positive on vaccines than many, us included, ever expected he could be. Public messaging has shifted — at least superficially — toward nutrition, chronic disease, and the Make America Healthy Again agenda. Kennedy even acknowledged in a recent congressional hearing that the measles, mumps, and rubella vaccine is safe and effective “for most people.” 

But this lull in anti-vaccine rhetoric and action should not be mistaken for a durable pivot in federal vaccine policy. It is a cynical, political pause: the eye of a storm shaped more by electoral timing than public health strategy. 

Read the rest…

Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined.

Conditions: Autism Spectrum Disorder; Autism

Interventions: Procedure: Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells; Dietary Supplement: Fecal Biomicrome Transplantation (FMT); Dietary Supplement: Ketogenic RESET Diet Protocol; Behavioral: Trial combines use of cSVF and MSCs (cryopres) with diet modification and FMT (fecal material Transplant in adult ASD patients; Dietary Supplement: FMT (Fecal Material Tranplantation); Biological: Use autologous cSVF + MSCs (cryo) for management of autoimmune component, anti-inflammatory and immune modulation

Sponsors: Black Tie Medical, Inc.

Enrolling by invitation

STAT+: Publicly, Kennedy embraces a more moderate MAHA

WASHINGTON — Health secretary Robert F. Kennedy Jr. once said there are no vaccines that are safe and effective. On Wednesday, he seemed to have changed his tune.

Across two Senate hearings, Kennedy noted that as health secretary, he funded the development of new vaccines, green-lit new shots for patients, asserted flu vaccines are preventive care, and even urged “every child to get the MMR,” a shot he previously suggested wasn’t safe. Last week, he acknowledged the shot could have saved the life of a child who died of measles.

Kennedy’s agenda continues to make waves across American health care, as his department pursues a broad crackdown on alleged fraud and seeks to upend Americans’ relationship with ultra-processed foods, all after major cuts across health agencies and a reworking of vaccine policy. But the about-face expands to a number of core MAHA issues — chemicals in food and the government’s relationship with industry among them.

It comes as some leaders of the insurgent movement have grown skeptical of the administration they rallied to support, forcing the Trump administration to thread the needle between courting the MAHA base’s ongoing support and dropping MAHA priorities seen as impractical or politically unwise. 

Continue to STAT+ to read the full story…

STAT+: Federal test of AI prior authorization is delaying care for seniors, report says

Washington state hospitals say their Medicare patients are waiting two to four times longer in some cases for procedures that are now subject to prior authorization under a new Medicare program. 

The report from Sen. Maria Cantwell (D-Wash.) is among the first to document alleged patient harm stemming from the Centers for Medicare and Medicaid Services’ new Wasteful and Inappropriate Service Reduction, or WISeR, Model. Cantwell is one of several Democratic members of Congress who have been urging CMS to scrap the program, which launched Jan. 1. 

Cantwell aired her concerns about WISeR to Health and Human Services Secretary Robert F. Kennedy Jr. at a Senate Committee on Finance hearing Wednesday. She said CMS is using artificial intelligence as a “denial device” and that patients are waiting weeks to get sign off for services that previously didn’t require approval. 

Continue to STAT+ to read the full story…